[Radiotherapy and PD-L1 Expression].

Area of Science:

• Oncology
• Immunology
• Radiation Oncology

Background:

• Combination therapy of radiotherapy and anti-PD-1/PD-L1 antibodies shows promise in cancer treatment.
• Radiotherapy modulates the tumor microenvironment, inducing both immune stimulation and suppression.
• PD-L1 expression on cancer cells hinders T cell function, contributing to immune escape.

Purpose of the Study:

• To review the mechanisms by which radiotherapy induces PD-L1 upregulation.
• To understand the intricate regulation of PD-L1 expression in response to radiotherapy.
• To provide a basis for optimizing combination immuno-radiotherapy strategies.

Main Methods:

• Review of preclinical studies and existing research on PD-L1 upregulation.
• Analysis of four key pathways involved in radiotherapy-induced PD-L1 expression: IFN-γ signaling, EGFR, DNA damage, and cGAS-STING.
• Examination of the role of the JAK/STAT pathway in mediating PD-L1 upregulation.

Main Results:

• Radiotherapy induces PD-L1 upregulation via IFN-γ signaling, EGFR, DNA damage, and cGAS-STING pathways.
• These pathways converge through the JAK/STAT signaling cascade.
• PD-L1 upregulation is a key mechanism in cancer immune escape and can affect treatment efficacy.

Conclusions:

• Understanding radiotherapy-induced PD-L1 upregulation mechanisms is crucial for developing effective combination therapies.
• This knowledge can guide personalized immuno-radiotherapy approaches.
• Further research into the complex regulation of PD-L1 is needed for optimal treatment strategies.